The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Exparel
bupivacaine · BUPIVACAINE 13.3 mg/mL · Injection, Suspension, Liposomal · Infiltration · Pacira Pharmaceuticals, Inc.
NDC 65250-0133-04 · 4 VIAL in 1 CARTON / 10 mL in 1 VIAL · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$1.45per billing unit (1 MG)HCPCS J0666 · Jul 1, 2026
- Federal ceiling (Big4)$623.82per package of 4X10MLPacira Pharmaceuticals · Jan 1, 2026
- List price (WAC, as filed)$1,013.41per packagePacira Pharmaceuticals, Inc. · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,013.41
Reported to Texas DSHS · 2026 annual filing · Pacira Pharmaceuticals, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$1.454
HCPCS J0666 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$241,649
1,199 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Pacira Pharmaceuticals, Inc.United Statesanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA022496
- TE code
- —
- Approval date
- Oct 28, 2011
- Patents / exclusivity
- 42 patents, 2 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | I-929 | Nov 9, 2026 |
| exclusivity | I-929 | Nov 9, 2026 |
| patent | 12318483 | Jul 2, 2044 |
| patent | 12318483 | Jul 2, 2044 |
| patent | 12251468 | Jul 2, 2044 |
| patent | 12251468 | Jul 2, 2044 |
| patent | 12370142 | Jul 2, 2044 |
| patent | 12370142 | Jul 2, 2044 |
| patent | 12156940 | Jul 2, 2044 |
| patent | 12156940 | Jul 2, 2044 |
| patent | 12226610 | Feb 2, 2043 |
| patent | 12226610 | Feb 2, 2043 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedNov 21, 2019Pacira Pharmaceuticals, Inc. — Sub Potent Drug: Out of Specification (OOS)
Manufacturers of bupivacaine (Injection, Suspension, Liposomal)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Pacira Pharmaceuticals, Inc. | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Patheon UK Limited | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Exparel — NDC 65250-0133-04," retrieved September 3, 2026, https://drugdashboards.com/drug/65250013304.
Free to cite with attribution — see how the data is put together.